Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease
- 22 March 2010
- journal article
- review article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 38 (2) , 545-551
Abstract
Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer199−202>pSer214>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.Keywords
This publication has 34 references indexed in Scilit:
- Why is the amyloid beta peptide of Alzheimer's disease neurotoxic?Dalton Transactions, 2008
- Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional ImprovementsThe Journal of Neuroscience, 2007
- Secretory trafficking in neuronal dendritesNature Cell Biology, 2004
- Triple-Transgenic Model of Alzheimer's Disease with Plaques and TanglesNeuron, 2003
- The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodiesFEBS Letters, 2002
- Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?Journal of Neurology, Neurosurgery & Psychiatry, 2001
- Conformational change as one of the earliest alterations of tau in Alzheimer's diseaseNeurobiology of Aging, 2000
- Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitroCell and tissue research, 2000
- The Road Less Traveled: Emerging Principles of Kinesin Motor UtilizationAnnual Review of Cell and Developmental Biology, 1999
- Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule bindingNeuron, 1993